BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cord Blood America, Inc. Files Preliminary Proxy Statement


7/17/2012 10:29:13 AM

LAS VEGAS, July 13, 2012 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC-BB: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that it has filed a Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & Exchange Commission (www.sec.gov).

As detailed in its July 9, 2012 press release, the successful negotiation of the debt restructuring and the BioCells settlement agreement has positioned CBAI to eliminate its remaining debt obligations. The majority of the amount of common stock sought in the increase stems directly from the recently executed Tonaquint note and the legacy St. George note. For Tonaquint, CBAI is contractually obligated to reserve 225,000,000 shares, which is approximately two times the debt coverage of the note. With St. George, the note requires a similar reserve equal to at least 200% of the number of shares of common stock that would be needed to fully convert the note and associated warrants. The balance of the increase is for the Company's debt obligations with Tangiers Investors, LP, along with any unanticipated contingencies. "These share reserve requirements exist as a safeguard, not a commitment to issue the entire reserve, and are commonly found in convertible debt instruments. These requirements are just another reason we wanted to terminate any additional requirements for funding under such arrangements and end this cycle," said newly appointed President, Joseph Vicente.

"We again ask you our shareholders to support management in this measure. We believe in eight short weeks we have demonstrated the seriousness in which we view dilution and have delivered results against its furtherance. We continue to be steadfast in our vision that a company with no long term debt and the ability to operate on its own cash has substantial opportunities for growth and stock appreciation. We look forward to releasing our operational results in upcoming quarters," Mr. Vicente said.

About Cord Blood America

Cord Blood America, Inc. is the parent company of CorCell Companies, Inc., which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. and CorCell Companies, Inc., visit our websites: http://www.corcell.com/ for customer information and http://www.cordblood-america.com/ for investor information.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect,'' "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Cord Blood America's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

CONTACT: Paul Knopick
E & E Communications
pknopick@eandecommunications.com
1-940-262-3584

SOURCE Cord Blood America, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES